Am J Transplant, Volume 18, Suppl 3 Archives - Page 175 of 211 - ATC Abstracts

2018 American Transplant Congress
PGE2/Beta-Catenin/XBP1 Signaling Controls Mesenchymal Stem Cell-Mediated Immune Regulation in Liver Ischemia and Reperfusion Injury
C. Li, S. Yue, L. Jiang, Q. Zhu, D. Farmer, R. Busuttil, J. Kupiec-Weglinski, B. Ke.
The Dumont-UCLA Transplant Center, Department of Surgery, Los Angeles, CA.
Background: Mesenchymal stem cells (MSCs) display profound immunomodulatory properties and tissue repairing capability under inflammatory conditions. However, it is unknown how MSCs may affect immunity…
2018 American Transplant Congress
Increasing the Donor Pool for Highly Sensitized Patients with Allele Specific Antibodies: Optimizing the Virtual Crossmatch (vXM)
A. Zhang,¹ Z. Zaky,² J. Africa,³ D. Good,¹ R. Bray,⁴ H. Gebel.⁴
¹Allogen Laboratories, Cleveland Clinic, Cleveland; ²Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland; ³Transplant Surgery, Charleston Area Medical Center, Charleston; ⁴Pathology & Laboratory Medicine, Emory University, Atlanta.
Background:Since implementation of the current Kidney Allocation System, highly sensitized patients with 98-100% cPRA (HSPs) are receiving ~10% of deceased donor kidneys compared to <2%…
2018 American Transplant Congress
The Living Donor Lost Wages Trial: Study Rationale, Protocol, and Update
J. Rodrigue,¹ M. Pavlakis,¹ A. Evenson,¹ A. Fleishman,¹ M. Carroll,¹ D. Mandelbrot,² P. Baliga,³ D. Howard,⁴ J. Schold.⁵
¹Beth Israel Deaconess Medical Center, Boston, MA; ²University of Wisconsin, Madison, WI; ³Medical University of South Carolina, Charleston, SC; ⁴Emory University, Atlanta, GA; ⁵Cleveland Clinic, Cleveland, OH.
Living donor kidney transplantation (LDKT) is the optimal treatment for adults with renal failure. However, living kidney donation has declined in the past decade, particularly…
2018 American Transplant Congress
Long-Term Medical, Financial, Psychosocial, and Overall Health-Related Quality of Life after Living Donation in Liver Transplantation
J. Emamaullee,¹ L. Sher,¹ T-.L. Fong,² K. Dhanireddy,¹ S. Zielsdorf,¹ C. Romero,¹ N. Wade,¹ Y. Genyk.¹
¹Surgery, University of Southern California, Los Angeles, CA; ²Keck School of Medicine at the University of Southern California, Los Angeles, CA.
Background: The long-term impact of living donation (LD) in liver transplantation on health-related quality of life (HRQOL) has not been well characterized. This study was…
2018 American Transplant Congress
Outcomes after HIV+ Liver Transplant: A HOPE in Action Study
C. Durand,¹ M. Bowring,¹ A. Tobian,^1,3 D. Brown,¹ A. Cameron,¹ S. Ottman,¹ K. Oshima,¹ D. Ostrander,¹ A. Redd,¹ S. Huprikar,² B. Haydel,² S. Lerner,² S. Florman,² S. Chandran,⁶ A. Chao,⁶ V. Kirchner,⁷ T. Pruett,⁷ A. Massie,¹ D. Segev.¹
¹JHU, Baltimore; ²Mount Sinai, New York; ³NIH, Bethesda; ⁴UCSF, San Francisco; ⁵UMN, Minneapolis.
The HOPE in Action Pilot Trial (NCT02602262) is assessing the safety and feasibility of HIV+ deceased donor (D+) kidney and liver transplantation for HIV+ recipients…
2018 American Transplant Congress
Impact of Ambulatory Transplant Pharmacy Services on Outcomes and Readmissions in Adult Abdominal Transplant Recipients
K. Joyal,¹ C. Rogers,² M. Cote,² M. Pavlakis,² A. Evenson,² V. Patwardhan,² K. Richards.²
¹Northeastern University, Boston, MA; ²Beth Israel Deaconess Medical Center, Boston, MA.
Over the past two decades, the role of transplant pharmacists (Txp Rx) has expanded following revised guidance from UNOS and CMS. There is little data…
2018 American Transplant Congress
Early Results from USHER: A Pilot Trial of Transplanting HCV-Infected Hearts into HCV-Negative Recipients Followed by Anti-Viral Therapy
R. McLean, P. P. Reese, M. Acker, P. Abt, A. Sicilia, N. Hornsby, P. Atluri, K. R. Reddy, E. Blumberg, V. Van Deerlin, D. S. Goldberg.
UPENN, Philadelphia.
Background: In 2016, over 600 hearts from deceased donors with active or prior hepatitis C virus (HCV) infection were discarded; most were otherwise good quality,…
2018 American Transplant Congress
The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy?
A. Assounga,^1,2 S. Omarjee.¹
¹Dept of Nephrology, University of KwaZulu-Natal, Durban, South Africa; ²Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Background:Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented. However, trial…
2018 American Transplant Congress
Patients Converted to Belatacept Show Different Immunophenotyping Compared with De Novo Belatacept-Treated Patients
M. Rial,¹ F. Caro,² A. Nella,² D. Guerrieri,² L. León,¹ P. Uva,¹ E. Chuluyan,² D. Casadei.¹
¹Instituto de Nefrología, Nephrology, Buenos Aires, Argentina; ²CEFYBO, UBA, CONICET, Buenos Aires, Argentina.
The incidence of adverse clinical events mainly in early, but not late post-transplantation such as an increased rate of acute rejection precludes the use of…
2018 American Transplant Congress
Stress-Related Exosomal MicroRNA Biomarkers Released by Human Islets during Transplantation
P. Saravanan,¹ P. Nguyen,¹ G. Yoshimatsu,¹ C. Chang,¹ C. Darden,¹ R. Bhattacharjee,¹ X. Wang,¹ J. Gu,¹ M. Lawrence,¹ B. Naziruddin.²
¹Baylor Scott & White Research Institute, Dallas; ²Baylor Simmons Transplant Institute, Dallas.
Purpose: Pancreatic islets release noncoding microRNAs (miRNAs) upon damage and stress during islet transplant procedures. In this study, we sought to identify miRNAs released by…